Synaptogenix Has Been Granted U.S. Patent Number 12,016,837 Titled "Halogenated Esters Of Cyclopropanated Unsaturated Fatty Acids For Use In The Treatment Of Neurodegenerative Diseases (Including Alzheimer's Disease)"
Portfolio Pulse from Benzinga Newsdesk
Synaptogenix has been granted U.S. Patent Number 12,016,837 for 'Halogenated Esters Of Cyclopropanated Unsaturated Fatty Acids For Use In The Treatment Of Neurodegenerative Diseases (Including Alzheimer's Disease)'.
June 25, 2024 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Synaptogenix has received a U.S. patent for a new treatment targeting neurodegenerative diseases, including Alzheimer's. This could enhance their product portfolio and market position.
The granting of a patent for a new treatment can significantly enhance Synaptogenix's product portfolio and market position, potentially leading to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100